Estrogen Receptor Positive Breast Cancer
Conditions
Brief summary
The goal of this interventional, prospective research on human bodily material is to discover new, cancer-specific molecular structures (i.e. glycopeptides) within surgically removed, estrogen receptor positive breast cancer tumors. The main goal it aims to achieve is: To discover tumor-specific targets, that allow the use of very potent immunotherapeutic drugs as treatment for solid tumors, such as estrogen receptor positive breast cancer. These new targets are very specific for cancer cells, meaning that virtually no healthy cells should be attacked by the treatment, resulting in less side effects. Participants will undergo standard of care treatment, comprising surgical removal of the breast tumor. Part of these tissues will be used for this clinical research.
Interventions
PROCEDURETumor resection
As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
Sponsors
University Hospital, Ghent
Algemeen Ziekenhuis Maria Middelares
University Ghent
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female * Minimally 18 years old * Diagnosed with estrogen-receptor positive breast cancer * This must be a primary tumor
Exclusion criteria
* Male * Younger than 18 years old * Previous history of other tumors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Discovery of new, tumor-specific, glycopeptide epitopes. | The patients are only involved during their standard of care surgery (one day). The discovered epitopes will not be shared with enrolled patients. | The discovery of new antigens, comprising both glycan and peptide (=glycopeptide), on the outside of the plasma membrane of the breast cancer cells. These antigens should be absent on healthy cells. These new, glycopeptide antigens can be used as target for immunotherapeutics against cancer. |
Countries
Belgium
Outcome results
None listed